DYN Dyne Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818794 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.7%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-74.6%
ROA-57.6%
ROIC (approx.)-225.2%
Asset turnover—
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.21x
Current ratio12.99x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-3.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $161.74M | $152.17M | $100.89M | $95.43M | $97.22M | $99.24M | $106.45M | $81.81M |
| SG&A expense | $35.33M | $29.49M | $24.39M | $20.70M | $16.67M | $16.55M | $15.93M | $15.30M |
| Operating income | -$197.07M | -$181.66M | -$125.28M | -$116.13M | -$113.89M | -$115.79M | -$122.37M | -$97.11M |
| Interest expense | — | — | — | — | $2.90M | $94,000 | — | — |
| Net income | -$193.55M | -$178.56M | -$120.85M | -$111.95M | -$108.04M | -$110.86M | -$115.36M | -$89.54M |
| EBITDA | -$196.47M | -$181.06M | -$124.73M | -$115.61M | -$113.39M | -$115.29M | -$121.87M | -$96.66M |
| EPS (basic) | -1.06 | -1.08 | -0.73 | — | -0.76 | -0.97 | -1.05 | — |
| EPS (diluted) | -1.06 | -1.08 | -0.73 | — | -0.76 | -0.97 | -1.05 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $913.20M | $676.11M | $753.10M | $893.37M | $573.61M | $485.04M | $472.25M | $435.45M |
| Short-term investments | $221.18M | $222.36M | $219.05M | $217.19M | $218.28M | $198.88M | $205.24M | $206.82M |
| Current assets | $1.18B | $937.89M | $1.02B | $1.13B | $806.26M | $697.95M | $689.50M | $659.28M |
| PP&E, net | $7.14M | $24.56M | $23.68M | $24.03M | $23.97M | $5.67M | $5.75M | $5.40M |
| Total assets | $1.23B | $994.01M | $1.08B | $1.19B | $867.06M | $728.99M | $721.07M | $691.23M |
| Current liabilities | $90.55M | $78.03M | $51.25M | $50.62M | $59.85M | $41.47M | $33.88M | $42.26M |
| Long-term debt | $200.01M | $199.33M | $149.38M | $148.92M | $99.15M | $98.81M | — | $0 |
| Total debt | $200.01M | $199.33M | $149.38M | $148.92M | $99.15M | $98.81M | — | $0 |
| Total liabilities | $303.87M | $291.86M | $214.90M | $214.83M | $175.28M | $157.55M | $52.10M | $61.40M |
| Shareholders' equity | $930.93M | $702.15M | $865.05M | $972.13M | $691.78M | $571.45M | $668.97M | $629.84M |
| Net debt | -$713.19M | -$476.79M | -$603.73M | -$744.45M | -$474.46M | -$386.23M | — | -$435.45M |
| Shares outstanding | 187.33M | 165.67M | 165.20M | 164.95M | 142.61M | 114.34M | 113.63M | 102.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$177.49M | -$130.29M | -$144.92M | -$111.83M | -$90.78M | -$94.70M | -$105.89M | -$84.33M |
| Capital expenditure | $2.01M | $1.51M | $221,000 | $484,000 | $395,000 | $60,000 | $981,000 | $1.07M |
| Free cash flow | -$179.50M | -$131.80M | -$145.14M | -$112.32M | -$91.17M | -$94.76M | -$106.87M | -$85.41M |
| Investing cash flow | -$1.29M | -$4.79M | -$2.39M | $982,000 | -$37.97M | $6.77M | $1.46M | -$16.01M |
| Financing cash flow | $418.10M | $58.11M | $7.06M | $430.96M | $217.33M | $100.77M | $141.24M | $3.64M |
| Depreciation & amortization | $600,000 | $600,000 | $550,000 | $521,000 | $500,000 | $500,000 | $502,000 | $450,000 |
| Stock-based compensation | $16.21M | $14.98M | $13.08M | $11.23M | $11.08M | $10.52M | $13.02M | $10.48M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.